Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer

(A) Original core biopsy at low power; hematoxylin and eosin stain (H&E), 100X. (B) Original core biopsy at high power; H&E, 400X. Courtesy of James C. Steinmetz, MD, Department of Pathology, Moses Taylor Hospital, Scranton, PA

(A) Residual ductal carcinoma in lymph node; H&E, 100X. (B) Residual ductal carcinoma in lymph node; H&E, 400X. Courtesy of James C. Steinmetz, MD, Department of Pathology, Moses Taylor Hospital, Scranton, PA.

(A) Original core biopsy at low power; H&E, 10X. (B) Original core biopsy at high power; H&E, 40X. Courtesy of Hasam Hamati, MD, Department of Pathology, Mercy Hospital Health Partners, Scranton, PA.

(A) Fibrotic breast tumor post-treatment at low power; H&E, 10X. (B) Fibrotic breast tumor post-treatment at high power; H&E, 40X. Courtesy of Hasam Hamati, MD, Department of Pathology, Mercy Hospital Health Partners, Scranton, PA.

(A) Residual ductal carcinoma in lymph node; H&E, 10X. (B) Residual ductal carcinoma in lymph node; H&E, 40X. Courtesy of Hasam Hamati, MD, Department of Pathology, Mercy Hospital Health Partners, Scranton, PA.